The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $93.00. The company’s shares closed last Friday ...

The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The ...

Fintel reports that on September 16, 2024, JP Morgan upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS ...